Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + umifenovir versus hydroxychloroquine for moderate COVID-19
IRCT20200325046859N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydroxychloroquine and umifenovir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Mortality rate. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquineumifenovir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200325046859N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200325046859N2.